SCHEMBL3018259

SCHEMBL3018259

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
FABP4 P15090 3/20 0.36
TP53 P04637 1/20 0.35
OGA O60502 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011668 0.94 DPP8 (0.41) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL3001916 0.90 DPP8 (0.40) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL3019563 0.87 ALDH1A1 (0.38) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL3002541 0.86 OGA (0.33) MEN1KMT2ALMNAMAPK1ALDH1A1
SCHEMBL2997910 0.86 MEN1 (0.44) MEN1KMT2ALMNAMAPK1ALDH1A1
SCHEMBL3008179 0.86 DPP8 (0.39) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL3015626 0.85 MEN1 (0.44) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL3009137 0.85 KMT2A (0.42) MEN1KMT2ALMNAMAPK1ALDH1A1
SCHEMBL3006389 0.85 ALDH1A1 (0.41) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL3011840 0.85 ALDH1A1 (0.39) PIK3CDPIK3CAPIK3CBPIK3CGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA PIK3CD 1507/4885PIK3CA 2320/4885PIK3CB 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.